Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages

  Rei, Margarida ^a,b,c   Gonca̧lves Sousa, Natacha ^b   Lanca̧, Telma ^b,d   Thompson, Richard G ^a   Mensurado, Sofia ^b   Balkwill, Frances R ^a   Kulbe, Hagen ^a,e   Pennington, Daniel J ^a   Silva Santos, Bruno ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gamma delta T cells; Tumor immunology

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; T LYMPHOCYTE RECEPTOR; AUTACOID; CD27 ANTIGEN; IL17R PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR; T-CELL RECEPTOR VGAMMA6, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CD27 - V GAMMA G + GAMMA DELATA T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM EXUDATE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL MOTION; CLASSIFICATION; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD27; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, INTERLEUKIN-17; T-LYMPHOCYTE SUBSETS;

EID: 84906705993     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1403424111     Document Type: Article

References (69)

1. Lança T, Silva-Santos B (2012) The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. OncoImmunology 1(5):717-725.
2. Hayday AC (2009) Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31(2):184-196.
3. Street SE, et al. (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 199(6):879-884. (Pubitemid 38375207)
4. Girardi M, et al. (2001) Regulation of cutaneous malignancy by gammadelta T cells. Science 294(5542):605-609. (Pubitemid 32999559)
5. Liu Z, et al. (2008) Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180(9):6044-6053.
6. Gao Y, et al. (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198(3):433-442. (Pubitemid 36976054)
7. Lança T, et al. (2013) Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 190(12):6673-6680.
8. Gibbons DL, et al. (2009) Neonates harbour highly active gammadelta T cells with selective impairments in preterm infants. Eur J Immunol 39(7):1794-1806.
9. CorvaisierM, et al. (2005) V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481-5488. (Pubitemid 41456435)
10. Wrobel P, et al. (2007) Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: Involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 66(2-3):320-328. (Pubitemid 47063194)
11. Gomes AQ, et al. (2010) Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells. Haematologica 95(8):1397-1404.
12. Lança T, et al. (2010) The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood 115(12):2407-2411.
13. Fournié JJ, et al. (2013) What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 10(1):35-41.
14. Gomes AQ, Martins DS, Silva-Santos B (2010) Targeting γδ T lymphocytes for cancer immunotherapy: From novel mechanistic insight to clinical application. Cancer Res 70(24):10024-10027.
15. Hannani D, et al. (2012) Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 33(5):199-206.
16. Ma C, et al. (2012) Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189(10):5029-5036.
17. Wu P, et al. (2014) γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40(5):785-800.
18. Wakita D, et al. (2010) Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 40(7):1927-1937.
19. Ma S, et al. (2014) IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 74(7):1969-1982.
20. Ribot JC, et al. (2009) CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol 10(4):427-436.
21. Ribot JC, et al. (2010) Cutting edge: adaptive versus innate receptor signals selectively control the pool sizes of murine IFN-γ- or IL-17-producing γδ T cells upon infection. J Immunol 185(11):6421-6425.
22. Turchinovich G, Pennington DJ (2011) T cell receptor signalling in γδ cell development: Strength isn't everything. Trends Immunol 32(12):567-573.
23. Charles KA, et al. (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119(10):3011-3023.
24. Duraiswamy J, Freeman GJ, Coukos G (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73(23):6900-6912.
25. Leinster DA, et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol 227(2):136-145.
26. Kulbe H, et al.; Australian Ovarian Cancer Study Group (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66-75.
27. Prinz I, Silva-Santos B, Pennington DJ (2013) Functional development of γδ T cells. Eur J Immunol 43(8):1988-1994.
28. Serre K, Silva-Santos B (2013) Molecular mechanisms of differentiation of murine proinflammatory γδ T cell subsets. Front Immunol 4:431.
29. Roark CL, et al. (2004) Subset-specific, uniform activation among V gamma 6/V delta 1+ gamma delta T cells elicited by inflammation. J Leukoc Biol 75(1):68-75. (Pubitemid 38166781)
30. Michel ML, et al. (2012) Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing γδ cells. Proc Natl Acad Sci USA 109(43):17549-17554.
31. Silva-Santos B (2010) Promoting angiogenesis within the tumor microenvironment: The secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 40(7):1873-1876.
32. Numasaki M, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101(7):2620-2627. (Pubitemid 36857622)
33. Numasaki M, et al. (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175(9):6177-6189. (Pubitemid 41508106)
34. Cain DW, et al. (2013) Identification of a tissue-specific, C/EBPβ-dependent pathway of differentiation for murine peritoneal macrophages. J Immunol 191(9):4665-4675.
35. Ghosn EE, et al. (2010) Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA 107(6):2568-2573.
36. De Palma M, et al. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211-226. (Pubitemid 41317592)
37. Venneri MA, et al. (2007) Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109(12):5276-5285. (Pubitemid 46890548)
38. Pucci F, et al. (2009) A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114(4):901-914.
39. Coffelt SB, et al. (2010) Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 70(13):5270-5280.
40. Okabe Y, Medzhitov R (2014) Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157(4):832-844.
41. Motz GT, Coukos G (2011) The parallel lives of angiogenesis and immunosuppression: Cancer and other tales. Nat Rev Immunol 11(10):702-711.
42. Schmolka N, et al. (2013) Epigenetic and transcriptional signatures of stable versus plastic differentiation of proinflammatory γδ T cell subsets. Nat Immunol 14(10):1093-1100.
43. Sutton CE, et al. (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31(2):331-341.
44. Sheridan BS, et al. (2013) γδ T cells exhibit multifunctional and protective memory in intestinal tissues. Immunity 39(1):184-195.
45. Street SE, et al. (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 199(6):879-884. (Pubitemid 38375207)
46. Shahrara S, Pickens SR, Dorfleutner A, Pope RM (2009) IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 182(6):3884-3891.
47. Shahrara S, et al. (2010) IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 184(8):4479-4487.
48. Barin JG, et al. (2012) Macrophages participate in IL-17-mediated inflammation. Eur J Immunol 42(3):726-736.
49. Ishida H, et al. (2013) IL-23 protection against Plasmodium berghei infection in mice is partially dependent on IL-17 from macrophages. Eur J Immunol 43(10):2696-2706.
50. Liu L, et al. (2012) Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7(7):1091-1100.
51. Hudson JD, et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190(10):1375-1382.
52. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3(10):791-800. (Pubitemid 37328657)
53. Hagemann T, et al. (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 6(7):1993-2002. (Pubitemid 47052489)
54. Kumar J, Ward AC (2014) Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta 1845(2):117-125.
55. Ma Y, et al. (2011) Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208(3):491-503.
56. Takeuchi A, et al. (2011) IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 41(1):246-251.
57. Hamada S, et al. (2008) IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol 181(5):3456-3463.
58. Martin-Orozco N, et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787-798.
59. Muranski P, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112(2):362-373.
60. Chalmin F, et al. (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36(3):362-373.
61. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114(2):357-359.
62. Wang L, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7):1457-1464.
63. He D, et al. (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184(5):2281-2288.
64. Chae WJ, et al. (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 107(12):5540-5544.
65. DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, Silva-Santos B (2011) CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptordriven activation of human γδ peripheral blood lymphocytes. Eur J Immunol 41(1):195-201.
66. Ness-Schwickerath KJ, Jin C, Morita CT (2010) Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 184(12):7268-7280.
67. Caccamo N, et al. (2011) Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 118(1):129-138.
68. Laggner U, et al. (2011) Identification of a novel proinflammatory human skinhoming Vγ9Vδ 2 T cell subset with a potential role in psoriasis. J Immunol 187(5):2783-2793.
69. Kulbe H, et al. (2007) The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67(2):585-592. (Pubitemid 46192196)